Up-dosing of nivolumab may induce serious immune-related adverse events. 2022

K Takamoto, and T Komori, and Y Ishida, and N Kambe, and K Kabashima
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

UI MeSH Term Description Entries
D007154 Immune System Diseases Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both. Immune Disorders,Immune System Disorders,Immunologic Diseases,Diseases of Immune System,Immune Diseases,Immunological Diseases,Disease, Immune,Disease, Immune System,Disease, Immunologic,Disease, Immunological,Disorder, Immune System,Immune Disease,Immune Disorder,Immune System Disease,Immune System Disorder,Immunologic Disease,Immunological Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074322 Antineoplastic Agents, Immunological Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS. Antineoplastic MAbs,Antineoplastics, Monoclonal Antibodies,Antineoplastics, Monoclonal Antibody,MAbs, Antineoplastic,Monoclonal Antibodies, Antineoplastic,Antibodies Antineoplastics, Monoclonal,Antineoplastic Monoclonal Antibodies,Immunological Antineoplastic Agents,Monoclonal Antibodies Antineoplastics,Monoclonal Antibody Antineoplastics
D000077594 Nivolumab A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA. BMS-936558,MDX-1106,ONO-4538,Opdivo,BMS 936558,BMS936558,MDX 1106,MDX1106,ONO 4538,ONO4538

Related Publications

K Takamoto, and T Komori, and Y Ishida, and N Kambe, and K Kabashima
October 2018, Journal for immunotherapy of cancer,
K Takamoto, and T Komori, and Y Ishida, and N Kambe, and K Kabashima
March 2022, The British journal of dermatology,
K Takamoto, and T Komori, and Y Ishida, and N Kambe, and K Kabashima
July 2018, JAMA oncology,
K Takamoto, and T Komori, and Y Ishida, and N Kambe, and K Kabashima
July 2018, JAMA oncology,
K Takamoto, and T Komori, and Y Ishida, and N Kambe, and K Kabashima
January 2024, Journal of pain and symptom management,
K Takamoto, and T Komori, and Y Ishida, and N Kambe, and K Kabashima
January 2023, In vivo (Athens, Greece),
K Takamoto, and T Komori, and Y Ishida, and N Kambe, and K Kabashima
April 2021, Medicine,
K Takamoto, and T Komori, and Y Ishida, and N Kambe, and K Kabashima
August 2021, BMJ case reports,
K Takamoto, and T Komori, and Y Ishida, and N Kambe, and K Kabashima
January 2017, Case reports in oncology,
K Takamoto, and T Komori, and Y Ishida, and N Kambe, and K Kabashima
January 2019, Therapeutics and clinical risk management,
Copied contents to your clipboard!